儿童颅咽管瘤的管理与结局:新加坡15年经验
该回顾性队列纳入2002年1月至2017年6月在新加坡一家三级中心治疗的12例经组织学确诊的儿童颅咽管瘤患者(年龄≤18岁),中位随访6.60年。总体生存率为75.0%(9例),复发率为58.0%(7例),中位复发时间5.87个月,中位无进展生存期4.16年。作者认为儿童颅咽管瘤的长期管理仍然困难。
要点
- 12例儿童颅咽管瘤患者中,5例(41.7%)行全切除术,7例(58.3%)行次全切除术。
- 总体生存率为75.0%(9例),复发率为58.0%(7例)。
- 中位复发时间5.87个月,中位无进展生存期4.16年。
核心结论
- 儿童颅咽管瘤的长期管理仍然困难,多次复发和长期神经内分泌后遗症损害患者生活质量。
- 作者认为,进一步研究复发和神经内分泌后遗症的管理以及改善这些患者结局的新疗法可能是必要的。
研究设计与样本
- 回顾性队列研究,纳入2002年1月至2017年6月在新加坡一家三级中心治疗的12例经组织学确诊的儿童颅咽管瘤患者(年龄≤18岁)。
- 收集人口学、临床表现、影像学数据、治疗细节、术后后遗症以及死亡和复发结局,生存分析采用Cox比例风险模型。
主要发现
- 中位随访时间6.60年(范围1.9-11.5年),平均年龄7.6岁(标准差4.8),7例(58.3%)为男性。
- 最常见首发症状为颅内压增高(7例,58.3%)、视力缺陷(6例,50.0%)和术前内分泌异常(2例,16.7%)。
- 5例(41.7%)行全切除术,7例(58.3%)行次全切除术。
- 总体生存率为75.0%(9例),复发率为58.0%(7例)。
- 中位复发时间5.87个月(范围0.23-33.7,四分位距15.8),中位无进展生存期4.16年(范围0.18-10.1,四分位距5.29)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Craniopharyngiomas arise from the Rathke pouch and account for 1.2%-18.4% of pediatric primary brain tumors. Despite relatively good survival outcomes, patients face long-term morbidity from recurrences, visual impairment, and endocrinopathies, which reduce quality of life. We examined the management of pediatric craniopharyngiomas, their recurrences, and subsequent neuroendocrine sequelae in a tertiary center in South-East Asia. METHODS: A retrospective cohort of 12 paediatric patients (aged ≤18 years) with histologically confirmed diagnosis of craniopharyngioma treated from January 2002 to June 2017 was conducted. Data collected included demographics, clinical presentation, imaging data, treatment details, postoperative sequelae, and outcomes on mortality and recurrence. Survival analysis was conducted using Cox-proportional hazards model. RESULTS: The median follow-up time was 6.60 years (1.9-11.5 years). The mean age was 7.6 years (standard deviation 4.8) and 7 patients (58.3%) were male. The most common presenting symptoms were raised intracranial pressure (7, 58.3%), visual deficits (6, 50.0%), and preoperative endocrine abnormalities (2, 16.7%). Five patients underwent gross total resection (41.7%), and 7 underwent subtotal resection (58.3%). Overall survival was 75.0% (9 patients), and recurrence was 58.0% (7 patients). Median time-to-recurrence was 5.87 months (0.23-33.7, interquartile range 15.8), and median progression-free survival was 4.16 years (0.18-10.1, interquartile range 5.29). CONCLUSIONS: Long-term management of pediatric craniopharyngioma remains difficult, with multiple recurrences and long-term neuroendocrine sequelae impairing quality of life for patients. Further research into management of recurrences and neuroendocrine sequelae, as well as novel therapies to improve outcomes in these patients, may be warranted.
引用
- Lim MJR, Wee RGM, Aw NMY, et al. Management and Outcomes of Pediatric Craniopharyngioma: A 15-Year Experience in Singapore. World Neurosurg. 2023. PMID: 37406798. doi:10.1016/j.wneu.2023.06.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。